Abbott have received CE Marking for their Alinity™ m diagnostics system and assays. This new technology will help keep up with the growing demand for infectious disease testing. Alinity m will provide unprecedented flexibility in molecular diagnostic testing, allowing more tests to be done in shorter timeframes, while reducing the space and number of instruments needed to conduct large amounts of tests.

"To design Alinity m, we spent countless hours with hundreds of lab directors around the world to address the challenges they face, including higher testing volumes, managing complex, labor-intensive processes and doing so with less time and space," said John Carrino, divisional vice president, research and development, Molecular Diagnostics, Abbott. "Alinity m will dramatically increase efficiency while delivering accurate results that patients and healthcare professionals can trust to help make decisions about their health and treatment."

Alinity m provides unprecedented flexibility for lab staff and faster testing results for clinicians and patients.  Alinity m may also reduce the lab equipment footprint from four to six instruments down to one – decreasing the space requirements and hours spent learning and maintaining different instruments.

Now available in countries that recognize CE Mark, Alinity m offers initial assays including virologic testing for:

• human immunodeficiency virus type 1 (HIV-1),
• hepatitis B virus (HBV) and hepatitis C virus (HCV);
• sexual health-related testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium or CT/NG/TV/MG panel;
• and high-risk human papillomavirus (HPV) testing.

Local product availability may vary depending on geographic location. In the U.S., Alinity m is in development and is not commercially available for diagnostic use.

Visit www.corelaboratory.abbott/int/en/offerings/brands/Alinity